Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Weight loss isn’t just cosmetic; it prevents chronic disease, saves money and improves mental and physical well-being.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

A recent study published in the Journal of the American Dental Association found that Tirzepatide presented a novel strategy ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.